Companies
Kyushu University
the academic origin of the XY-to-XX chromosomal reprogramming technique and of ongoing work reconstituting germ-cell and gonadal development for in-vitro gamete production, published across Nature-family and Science journals and pursued in collaboration with European labs.
- Country
- Japan
ivg
research
eu
Coverage
| CN | EU | US | |
|---|---|---|---|
| regenerative-personalized | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Affiliation | Department of Stem Cell Biology and Medicine, Graduate School of Medical Sciences, Kyushu University (2022-06-29) | gwern.net · rep.bioscientifica.com · mdpi.com |
| Research focus | in vitro gametogenesis and reconstitution of germ-cell and gonadal development from pluripotent stem cells | doi.org · gwern.net · pubmed.ncbi.nlm.nih.gov · rep.bioscientifica.com · kyushu-u.ac.jp · mdpi.com · researchgate.net |
| Grant | JSPS KAKENHI Grants-in-Aid, Uehara Memorial Foundation, Takeda Science Foundation, Japan Agency for Medical Research and Development (AMED) | gwern.net · rep.bioscientifica.com · mdpi.com |
| Publications | Extensive publications in journals such as Nature, Science, and Biology on mouse oogenesis and germ cell reconstitution | doi.org · kyushu-u.elsevierpure.com · kyushu-u.ac.jp · mdpi.com |
| Principal staff | Katsuhiko Hayashi (Professor/Principal Investigator) | doi.org · prime.osaka-u.ac.jp · kyushu-u.ac.jp · osaka-u.ac.jp |
| Headcount | Includes graduate students and researchers; specific total headcount not provided medium confidence | kyushu-u.ac.jp · mdpi.com |
Independent sources: doi.org · gwern.net · kyushu-u.ac.jp · kyushu-u.elsevierpure.com · mdpi.com · osaka-u.ac.jp · prime.osaka-u.ac.jp · pubmed.ncbi.nlm.nih.gov · rep.bioscientifica.com · researchgate.net
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| In-vitro gametogenesis (IVG) & reproductive synbio | regenerative-personalized | High | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.